Assessing psychological support for people with emotional distress and difficulties in relationships: The SPS study

ISRCTN ISRCTN13918289
DOI https://doi.org/10.1186/ISRCTN13918289
IRAS number 315951
Secondary identifying numbers CPMS 53799, IRAS 315951
Submission date
03/11/2022
Registration date
11/11/2022
Last edited
20/02/2025
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
People with a diagnosis of personality disorder have high levels of contact with health services but the care they receive is often poor. National guidelines recommend that people are offered evidence-based psychological treatments. These treatments last between one to two years and require people to attend therapy groups on a regular basis, but these intensive treatments are not suitable for everyone with a personality disorder. In an effort to provide services that are more inclusive and to increase the number of people with a personality disorder that receive effective treatment, clinicians have begun to develop lower-intensity treatments. However, we do not have good quality evidence about whether they help patients in the long term or provide value for money. Structured Psychological Support (SPS) is an individual low-intensity intervention, which was developed in collaboration with people with lived experience of personality disorder. The aims of this study are to test whether SPS is a clinically and cost-effective intervention for improving mental health and social functioning in people with a probable personality disorder. The study also aims to conduct a parallel process evaluation where people that have been involved in the study tell us about their experiences. This will help the researchers gain a better understanding of the reasons for the study findings.

Who can participate?
Adults who are being treated by mental health staff working in a primary or secondary care NHS setting, and meet criteria for probable personality disorder

What does the study involve?
We plan to conduct a randomised trial of SPS compared to treatment as usual in people with a probable personality disorder. Participants will have their mental health, social function and service use assessed at the beginning of the study and again at follow-up 6 and 12 months later. For those allocated to receive the SPS intervention, 6 to 10 sessions of person-centred psychological support will be offered. This aims to help people develop a better understanding of their difficulties and techniques that they can use to improve their mental health and functioning. In parallel to the trial, trial participants, non-participants and clinicians or
managers will be interviewed about their experience of the study processes.

What are the possible benefits and risks of participating?
By taking part in this study, participants will help trial researchers to find out whether SPS helps to improve the social functioning and mental health of people with emotional distress and difficulties in relationships. However, they will be required to give up some of their time to complete the interviews and the SPS sessions.

Where is the study run from?
Imperial College London (UK)

When is the study starting and how long is it expected to run for?
April 2022 to February 2025

Who is funding the study?
National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) programme (UK)

Who is the main contact?
Trial Coordinating Office, psych_trials@imperial.ac.uk

Contact information

Dr Verity Leeson
Scientific

Clinical Trials Manager
Imperial College London
Centre for Psychiatry
2nd Floor Commonwealth Building
Du Cane Road
London
W12 0NN
United Kingdom

Email v.leeson@imperial.ac.uk
Prof Mike Crawford
Principal Investigator

Division of Psychiatry
Imperial College London
2nd floor Commonwealth Building
Du Cane Road
London
W12 0NN
United Kingdom

ORCiD logoORCID ID 0000-0003-3137-5772
Phone +44 (0)203 313 4162
Email m.crawford@imperial.ac.uk
Dr Trial Coordinating Office
Public

Imperial College London
2nd floor Commonwealth Building
Du Cane Road
London
W12 0NN
United Kingdom

Email psych_trials@imperial.ac.uk

Study information

Study designMulticentre individually randomized parallel-group researcher-masked randomised-controlled trial with a parallel process evaluation and an integrated economic evaluation
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleAssessing psychological support for people with emotional distress and difficulties in relationships: The SPS study.
Study acronymSPS
Study hypothesisIndividuals with probable personality disorder who are offered Structured Psychological Support will have improved social functioning over a one-year period, compared to those offered enhanced treatment as usual.
Ethics approval(s)Approved 18/10/2022, London-Bromley REC (Temple Quay House, 2 The Square, Temple Quay, Bristol, BS1 6PN, UK; +44 (0)207 104 8118; bromley.rec@hra.nhs.uk), ref: 22/LO/0631
ConditionPersonality disorder
InterventionThis is a multicentre, individually randomised, parallel-group, researcher-masked, randomised controlled trial, including a parallel process evaluation and an integrated economic evaluation.
The trial will involve two linked phases. The first is an internal pilot study of four months of recruitment across all centres. Data from the internal pilot will be presented to the Trial Steering Committee (TSC) indexed against a priori stop/go criteria. The TSC will then advise the funder and the sponsor on whether the study should progress to phase 2. Phase 2 is the full trial, with further recruitment over a four-month period. All participants will be followed-up for 12 months.
Patients that are eligible and provide written informed consent will complete the screening assessment with a study researcher. Those that do not consent to take part will be asked if they would consider speaking to the process evaluation researcher later in the study about their reasons for declining, and this is noted on the screening log. If eligibility is confirmed they will then have their name and contact details passed to the trial coordinator who will randomise them to one of two treatment arms, with an equally likely chance of allocation. All trial participants will receive enhanced treatment as usual from mental health services, meaning that all have a jointly developed crisis plan. In addition, they will be receiving either no additional treatment (treatment as usual/TAU) or Structured Psychological Support (SPS).
As soon as practical after eligibility is confirmed, participants will also complete the baseline assessment which collects basic demographic and clinical data, social functioning, mental health, and quality of life.
Each participant will be contacted by the trial coordinator once they have been randomised, to inform them of their treatment allocation. We will also inform their clinical team of their allocation. If allocated to SPS, the participant's contact details will be given to an allocated therapist who will then make contact directly to initiate the treatment. Therapy sessions may be audio-recorded for therapist supervision and assessment of treatment fidelity. Therapists will complete a proforma for each therapy participant that details the number and length of sessions and techniques used, but these will use the participant's study ID rather than name as an identifier.
Participants will be asked to complete further follow-up interviews at six and 12 months after randomisation. They will also be contacted by telephone at three and nine months to thank them for their participation in the study, remind them of their forthcoming follow-up interviews, confirm their contact details and inquire about any adverse events.
Some participants (50) and staff (up to 45) involved in the study will also be invited to interview for the process evaluation. Staff and patients will be selected purposively, to ensure that both men and women of different ages and ethnic and cultural backgrounds are included from a range of study sites. The qualitative researcher based at Middlesex University will work with the researchers at study sites to identify participants and staff that were involved in the study. The researcher that is based at the site and already known to the participant/staff member would approach them about the process evaluation interview and then either the site researcher or qualitative researcher will take consent. The qualitative researcher will carry out the interview either in-person or over the telephone/video call. Those that agree to take part will be audio-recorded and those recordings will be professionally transcribed verbatim prior to data analysis. For participants who wish to take part in the interview but do not want to be audio-recorded, the researcher will make contemporaneous notes, and then dictate as soon as possible after the interview has been completed.
Intervention typeBehavioural
Primary outcome measureSocial functioning measured using the Work and Social Adjustment Scale total score at 6 and 12 months
Secondary outcome measures1. Mental health measured using the 16-item Difficulties in Emotion Regulation Scale, the nine-item Patient Health Questionnaire, and the seven-item Generalised Anxiety Disorder scale at 6 and 12 months
2. Suicidal thoughts and behaviour measured using items from the National Household Survey of Psychiatric Morbidity scale at 6 and 12 months
3. Health-related quality of life measured using the EQ-5D-5L at 6 and 12 months
4. Patient experience measured using the patient-rated Global Improvement scale and the patient-rated Satisfaction with Care scale at 6 and 12 months
5. Personality status measured using the Standardised Assessment of Personality – Abbreviated Scale at 6 and 12 months
Overall study start date01/04/2022
Overall study end date28/02/2025

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned Sample Size: 308; UK Sample Size: 308
Total final enrolment336
Participant inclusion criteriaCurrent inclusion criteria as of 31/08/2023:
1. Probable personality disorder on the Standardised Assessment of Personality Abbreviated Scale (score of 4 or more)
2. Age 18 years old and over
3. Being treated by mental health staff working in a primary or secondary care NHS setting

Process evaluation:
4. Involved in the trial in any way or have indicated an interest in talking about their reasons for declining as part of the process evaluation if they declined when initially approached

Previous inclusion criteria:
Trial involvement:
1. Age 18 years old and over
2. Being treated by mental health staff working in a primary or secondary care NHS setting

Process evaluation:
3. Involved in the trial in any way or have indicated an interest in talking about their reasons for declining as part of the process evaluation if they declined when initially approached
Participant exclusion criteriaCurrent exclusion criteria as of 31/08/2023:
1. Unable or unwilling to provide written informed consent
2. Co-existing organic or psychotic mental disorder
3. In receipt of psychological treatment for personality disorder or are on a waiting list of <1 year for such treatment
5. Anyone currently a participant in a clinical trial or other interventional research will not be eligible to take part until their participation is complete

Previous exclusion criteria:
1. Probable personality disorder on the Standardised Assessment of Personality Abbreviated Scale
2. Unable or unwilling to provide written informed consent
3. Co-existing organic or psychotic mental disorder
4. In receipt of psychological treatment for personality disorder or are on a waiting list for such treatment
5. Anyone currently a participant in a clinical trial or other interventional research will not be eligible to take part until their participation is complete.
Recruitment start date06/02/2023
Recruitment end date31/01/2024

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centres

Central and North West London NHS Foundation Trust
Trust Headquarters
350 Euston Road
Regents Place
London
NW1 3AX
United Kingdom
Oxford Health NHS Foundation Trust
Warneford Hospital
Warneford Lane
Headington
Oxford
OX3 7JX
United Kingdom
Avon and Wiltshire Mental Health Partnership NHS Trust
Bath NHS House
Newbridge Hill
Bath
BA1 3QE
United Kingdom
Mersey Care NHS Foundation Trust
V7 Building
Kings Business Park
Kings Drive
Prescot
L34 1PJ
United Kingdom
Lincolnshire Partnership NHS Foundation Trust
St George's
Long Leys Road
Lincoln
LN1 1FS
United Kingdom
Coventry and Warwickshire NHS Trust
Wayside House
Wilsons Lane
Coventry
CV6 6NY
United Kingdom
Middlesex University
Department of Mental Health & Social Work
Ground Floor Town Hall
The Burroughs
London
NW4 4BT
United Kingdom
Imperial College London
Division of Psychiatry
2nd Floor Commonwealth Building
Du Cane Road
London
W12 0NN
United Kingdom
Derbyshire Healthcare NHS Foundation Trust
Trust Headquarters
Kingsway Hospital
Kingsway
Derby
DE22 3LZ
United Kingdom

Sponsor information

Imperial College London
Hospital/treatment centre

C/o: Becky Ward
215, Level 2, Medical School Building
Norfolk Place
London
W2 1PG
England
United Kingdom

Phone +44 (0)207 594 9459
Email becky.ward@imperial.ac.uk
Website http://www.imperial.ac.uk/
ROR logo "ROR" https://ror.org/041kmwe10

Funders

Funder type

Government

National Institute for Health and Care Research
Government organisation / National government
Alternative name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
Location
United Kingdom

Results and Publications

Intention to publish date30/11/2025
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination plan1. Peer-reviewed scientific journals
2. Conference presentation
3. Publication on website

We will use a broad range of methods to communicate the results of this research to all stakeholders including both those who provide and use mental health services for people with a personality disorder. This will include written reports, presentations at conferences, social media, service user groups and professional bodies. We will publish our findings on the website of the National Institute for Health and Care Research and in widely read high-quality peer-reviewed open-access journals. We will present the results of the study at the leading conferences for mental health and personality disorder.
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Prof. Mike Crawford (m.crawford@imperial.ac.uk). De-identified participant-level data including primary and secondary outcome measures and adverse events will be shared with researchers who provide a methodologically sound proposal by email to Prof. Crawford. The data will be available from 01/12/2024 with no fixed end date. Any data that could potentially be used to identify participants will not be provided in the dataset at the individual participant level e.g. ethnicity, and dates of service use. All participants gave written informed consent.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol file version 2.0 22/12/2022 31/01/2023 No No
HRA research summary 26/07/2023 No No
Protocol file version 4 18/07/2023 26/07/2023 No No
Protocol article 25/06/2024 28/06/2024 Yes No
Protocol file version 5.0 07/12/2023 06/11/2024 No No

Additional files

ISRCTN13918289_PROTOCOL_V2.0.pdf
ISRCTN13918289_Protocol_v4_18July2023.pdf
ISRCTN13918289_Protocol_v5.0_07Dec2023.pdf

Editorial Notes

20/02/2025: Total final enrolment added.
06/11/2024: The following changes were made:
1. Protocol uploaded (not peer-reviewed).
2. The overall study end date was changed from 30/11/2024 to 28/02/2025.
28/06/2024: Publication reference added.
04/01/2024: The study record was confirmed as being up to date.
31/08/2023: The inclusion and exclusion criteria were updated.
26/07/2023: The following changes were made to the study record:
1. Protocol uploaded (not peer reviewed).
2. The recruitment end date has been changed from 31/08/2023 to 31/01/2024.
3. Derbyshire Community Health Services NHS Foundation Trust was removed from the study participating centres.
4. Derbyshire Healthcare NHS Foundation Trust was added to the study participating centres.
31/01/2023: The following changes were made to the study record:
1. Protocol uploaded (not peer reviewed).
2. Contact details updated.
3. The recruitment start date was changed from 03/01/2023 to 06/02/2023.
03/11/2022: Trial's existence confirmed by NIHR (UK).